We recently attended Skyepharma’s capital markets day (CMD). Flutiform continues to post strong revenues, contributing directly to margins and underpinning strong growth in cash from operations. Post the CMD we have higher conviction for the potential mid- to long-term contributions from the respiratory assets in development, in particular the ground-breaking SKP-2075 for COPD/smoking asthma with headline Phase II data due in 2017 and SKP 2076, the triple therapy for asthma, which has p
04 Dec 2015
SKP-2075/SKP-2076: future stars aligning
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SKP-2075/SKP-2076: future stars aligning
We recently attended Skyepharma’s capital markets day (CMD). Flutiform continues to post strong revenues, contributing directly to margins and underpinning strong growth in cash from operations. Post the CMD we have higher conviction for the potential mid- to long-term contributions from the respiratory assets in development, in particular the ground-breaking SKP-2075 for COPD/smoking asthma with headline Phase II data due in 2017 and SKP 2076, the triple therapy for asthma, which has p